Why the study?
The pharmacokinetics, pharmacodynamics, and safety of the hepatically metabolized endothelin receptor antagonist ambrisentan had not been determined in children after Fontan surgery.
Does short-term oral ambrisentan improve hemodynamics and have a favorable pharmacokinetic and safety profile in children after Fontan surgery?
Does short-term oral ambrisentan improve hemodynamics and have a favorable pharmacokinetic and safety profile in children after Fontan surgery?
Ambrisentan exhibits reduced clearance after Fontan surgery but appears safe and provides beneficial hemodynamic effects in this pediatric population.
Short-term ambrisentan safely improves hemodynamics in pediatric Fontan patients; extends randomized evidence for endothelin antagonism to children.
No takes yet. Share an insight, caveat, or question.
Hill et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: